05.04.2017
Evotec AG DE0005664809
DGAP-News: EVOTEC ACHIEVES FIRST MILESTONE IN DIABETES ALLIANCE WITH SANOFI
DGAP-News: Evotec AG / Key word(s): Miscellaneous
EVOTEC ACHIEVES FIRST MILESTONE IN DIABETES ALLIANCE WITH SANOFI
05.04.2017 / 07:29
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Hamburg, Germany 05 April 2017: Evotec AG (Frankfurt Stock Exchange: EVT,
TecDAX, ISIN: DE0005664809) today announced that its strategic alliance
(TargetBCD) with Sanofi in the field of diabetes has reached an important
milestone, triggering a payment of EUR 3.0 m to Evotec, for achieving
pre-clinical proof-of-concept.
This milestone was achieved under the agreement between Evotec and Sanofi
signed in August 2015. The goal of this collaboration is to develop a beta
cell replacement therapy based on functional beta cells derived from human
stem cells. In addition, Sanofi and Evotec also aim to use human beta cells
for high-throughput drug screening to identify small molecules or biologics
beneficial for beta cell activity.
Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: "Diabetes
represents one of the major threats to global healthcare systems and we are
committed to discover new treatment options together with our colleagues at
Sanofi. We are very pleased to have achieved this very important milestone
that represents a major step forward towards developing a new therapeutic
option for diabetes patients."
ABOUT BETA CELLS
Beta cells play a key role in the pathogenesis of diabetes, a condition
which currently affects 415 million patients worldwide. Beta cells reside in
clusters of hormone producing cells ("islets") within the pancreas. They
respond to elevated blood glucose levels (e.g. after a meal) by secreting
the glucose lowering hormone insulin. In the type 1 form of diabetes
("T1D"), beta cells are destroyed by the patient's own immune system. As a
result, T1D patients have to follow a life-long regimen of carefully dosed
insulin injections. In patients with type 2 diabetes ("T2D"), beta cells are
functionally impaired and yet have to work in the presence of metabolic
stress and increased work load due to an impaired tissue insulin response.
T2D is progressive, and current therapeutic options cannot prevent the
deterioration of beta cell function, eventually also creating a need for
insulin injections. Insulin injections represent a significant burden to
patients. They cannot fully mimic the normal control of blood glucose levels
by normal beta cells, frequently resulting in debilitating acute and
long-term complications. There is an enormous medical need for novel
therapeutic options which can restore beta cell mass and thereby reduce or
eliminate the need for insulin injections, or which can prevent or reverse
the decline in beta cell function in type 2 diabetes.
ABOUT DIABETES
Diabetes mellitus ("Diabetes") is a chronic incapacitating disease
associated with severe lifelong conditions which require intensive
monitoring and control, such as cardiovascular diseases, kidney diseases,
nerve damage and eye diseases. At present, there is no cure for diabetes and
only symptomatic treatment options are available. According to the
International Diabetes Federation, approximately 415 million people
worldwide have diabetes in 2015 (2014: 387 million). Of these, about 46.5%
have not yet been diagnosed and are at risk of costly and debilitating
diabetes complications. Concerning the diabetes market volume, approx. $ 673
bn were spent on the treatment of diabetes in 2015 (2014: $ 612 bn).
ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies, academics, patient advocacy
groups and venture capitalists. We operate worldwide providing the highest
quality stand-alone and integrated drug discovery solutions, covering all
activities from target-to-clinic to meet the industry's need for innovation
and efficiency in drug discovery (EVT Execute). The Company has established
a unique position by assembling top-class scientific experts and integrating
state-of-the-art technologies as well as substantial experience and
expertise in key therapeutic areas including neuroscience, diabetes and
complications of diabetes, pain and inflammation, oncology and infectious
diseases. On this basis, Evotec has built a broad and deep pipeline of more
than 70 partnered product opportunities at clinical, pre-clinical and
discovery stages (EVT Innovate). Evotec has established multiple long-term
discovery alliances with partners including Bayer, CHDI, Sanofi or UCB and
development partnerships with e.g. Sanofi in the field of diabetes, with
Pfizer in the field of tissue fibrosis and Celgene in the field of
neurodegenerative diseases. For additional information, please go to
www.evotec.com and follow us on Twitter @EvotecAG.
FORWARD LOOKING STATEMENTS
Information set forth in this press release contains forward-looking
statements, which involve a number of risks and uncertainties. The
forward-looking statements contained herein represent the judgement of
Evotec as of the date of this press release. Such forward-looking statements
are neither promises nor guarantees, but are subject to a variety of risks
and uncertainties, many of which are beyond our control, and which could
cause actual results to differ materially from those contemplated in these
forward-looking statements. We expressly disclaim any obligation or
undertaking to release publicly any updates or revisions to any such
statements to reflect any change in our expectations or any change in
events, conditions or circumstances on which any such statement is based.
Contact Evotec AG:
Gabriele Hansen, VP Corporate Communications & Investor Relations, Phone:
+49.(0)40.56081-255, [email protected]
---------------------------------------------------------------------------
05.04.2017 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: [email protected]
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart, Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
562017 05.04.2017
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Evotec AG ISIN: DE0005664809 können Sie bei EQS abrufen
Biotechnologie , 566480 , EVT , XETR:EVT